December 10, 2019 · Phase 3 readout
AXSM Phase 3 readout: a positive outcome, +8.0%
On December 10, 2019, AXS-07 (MoSEIC meloxicam and rizatriptan) — Axsome Therapeutics, Inc. (Migraine) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +8.0% in the window around the event. It had already run +78.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$45.13
1d before
$48.75
Event day
$48.07
1d after
$46.79
5d after
Pre-catalyst setup
+78.4%
30-day run-up
61094%
30-day volatility